Fig. 2: Slc35e1 deficiency ameliorates the psoriasis-like phenotype in imiquimod (IMQ)-treated mice.
From: SLC35E1 promotes keratinocyte proliferation in psoriasis by regulating zinc homeostasis
Mice were subjected to a daily dose of 15 mg of IMQ cream per ear for 6 consecutive days. A The Psoriasis Area and Severity Index (PASI) score was recorded every day for both wild-type (WT) and Slc35e1-knockout (KO) mice (n = 3). B Hematoxylin and eosin (H&E) staining of non-lesional and lesional skin of WT (n = 6) and Slc35e1-KO (n = 6) mice with IMQ-induced psoriasis. (a, acanthosis; b, increased proliferative basal layer epidermal keratinocytes; c, dermal cell infiltrates; d, hyperkeratosis; e, parakeratosis. Left: Representative images. Right: Quantitative analysis of acanthosis in Slc35e1-KO and WT skin. C, D Infiltration of CD45+ leukocytes in the dermis and epidermis of WT (n = 4), KO (n = 4), WT + IMQ (n = 6), and KO + IMQ (n = 6) mice. C Epidermal (γδ T cells and Langerhans cells) and D dermal (neutrophils and γδ T cells) infiltration was detected by flow cytometry after treatment with dispase II. Left: Representative data. Right: Quantitative analysis. E The mRNA level of psoriatic inflammatory factors in the skin of WT (n = 3), KO (n = 3), WT + IMQ (n = 7), and KO + IMQ (n = 7) mice. Data are presented as means ± SEM; *P < 0.05, **P < 0.01, ***P < 0.001.
